RHYTHM PHARMACEUTICALS INC's ticker is RYTM and the CUSIP is 76243J105. A total of 128 filers reported holding RHYTHM PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.30 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $3,732,282 | -12.7% | 162,804 | -37.2% | 0.02% | -8.3% |
Q2 2023 | $4,276,583 | -6.1% | 259,344 | +1.6% | 0.02% | -22.6% |
Q1 2023 | $4,552,946 | -48.9% | 255,210 | -16.6% | 0.03% | -58.7% |
Q4 2022 | $8,911,099 | +38.7% | 306,013 | +16.7% | 0.08% | +10.3% |
Q3 2022 | $6,426,000 | +476.8% | 262,288 | +135.0% | 0.07% | +1033.3% |
Q4 2021 | $1,114,000 | +3.0% | 111,594 | +34.7% | 0.01% | -14.3% |
Q3 2021 | $1,082,000 | -33.5% | 82,854 | -0.2% | 0.01% | -30.0% |
Q2 2021 | $1,626,000 | -37.2% | 83,021 | -31.8% | 0.01% | -44.4% |
Q1 2021 | $2,588,000 | +789.3% | 121,667 | +1144.2% | 0.02% | +500.0% |
Q4 2020 | $291,000 | +26.0% | 9,779 | -8.4% | 0.00% | 0.0% |
Q3 2020 | $231,000 | -51.8% | 10,681 | -48.8% | 0.00% | -57.1% |
Q4 2019 | $479,000 | -20.7% | 20,847 | -25.5% | 0.01% | -22.2% |
Q3 2019 | $604,000 | +59.8% | 27,981 | +62.8% | 0.01% | +28.6% |
Q2 2019 | $378,000 | -2.3% | 17,187 | +21.8% | 0.01% | +16.7% |
Q1 2019 | $387,000 | – | 14,116 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
COMMODORE CAPITAL LP | 2,075,000 | $47,569,375 | 5.56% |
NEA Management Company, LLC | 2,909,956 | $66,710,741 | 5.15% |
Opaleye Management Inc. | 653,000 | $14,970,025 | 4.87% |
Frazier Life Sciences Management, L.P. | 2,371,304 | $54,362,144 | 3.61% |
VR Adviser, LLC | 1,090,000 | $24,988,250 | 2.63% |
RA Capital Management | 5,676,067 | $130,123,836 | 2.56% |
Samsara BioCapital, LLC | 345,293 | $7,915,842 | 2.42% |
SILVERARC CAPITAL MANAGEMENT, LLC | 260,537 | $5,972,811 | 1.81% |
Logos Global Management LP | 400,000 | $9,170,000 | 1.22% |
Cormorant Asset Management, LP | 850,000 | $19,486,250 | 1.14% |